{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "GBp", "marketState": "CLOSED", "regularMarketChangePercent": 0.0, "regularMarketPrice": 10.0, "exchange": "LSE", "shortName": "VALIRX PLC ORD 0.1P", "longName": "ValiRx plc", "messageBoardId": "finmb_28075629", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketTime": 1683904810, "earningsTimestamp": 1661943540, "earningsTimestampStart": 1685962740, "earningsTimestampEnd": 1686312000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.03, "epsForward": -1.86, "sharesOutstanding": 102320000, "bookValue": 0.044, "fiftyDayAverage": 10.1255, "fiftyDayAverageChange": -0.12549973, "fiftyDayAverageChangePercent": -0.012394423, "twoHundredDayAverage": 12.735355, "twoHundredDayAverageChange": -2.7353554, "twoHundredDayAverageChangePercent": -0.21478438, "marketCap": 10232000, "forwardPE": -0.05376344, "priceToBook": 227.27274, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1010390400000, "priceHint": 2, "regularMarketChange": 0.0, "regularMarketDayHigh": 10.3, "regularMarketDayRange": "9.6 - 10.3", "regularMarketDayLow": 9.6, "regularMarketVolume": 409040, "regularMarketPreviousClose": 10.0, "bid": 9.5, "ask": 10.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "LSE", "financialCurrency": "GBP", "regularMarketOpen": 10.3, "averageDailyVolume3Month": 509360, "averageDailyVolume10Day": 460177, "fiftyTwoWeekLowChange": 1.3249998, "fiftyTwoWeekLowChangePercent": 0.15273772, "fiftyTwoWeekRange": "8.675 - 28.9", "fiftyTwoWeekHighChange": -18.9, "fiftyTwoWeekHighChangePercent": -0.65397924, "fiftyTwoWeekLow": 8.675, "fiftyTwoWeekHigh": 28.9, "symbol": "VAL.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Stonebridge House", "address2": "Chelmsford Road", "city": "Hatfield", "zip": "CM22 7BD", "country": "United Kingdom", "website": "https://www.valirx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.", "fullTimeEmployees": 7, "companyOfficers": [{"maxAge": 1, "name": "Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D.", "age": 44, "title": "CEO & Director", "yearBorn": 1978, "fiscalYear": 2021, "totalPay": {"raw": 159183, "fmt": "159.18k", "longFmt": "159,183"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. James Gerry Desler FCA", "age": 66, "title": "CFO & Exec. Director", "yearBorn": 1956, "fiscalYear": 2021, "totalPay": {"raw": 48000, "fmt": "48k", "longFmt": "48,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kumar  Nawani", "title": "Head of Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Catherine Jane Tralau-Stewart Ph.D.", "title": "Chief Scientific Officer & Board Observer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Tarquin  Edwards", "title": "Head of Investor Relations & Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark  Treharne", "title": "Corp. Devel. Mang.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}